AI-generated summary
In this pilot randomized wait-list controlled trial, 25 head and neck cancer survivors with chronic lymphedema received either photobiomodulation (12 sessions over 6 weeks) or delayed treatment. The authors report improvements at 8 weeks in external lymphedema and fibrosis severity, symptom burden, and neck range of motion in the treated group, with no adverse events reported. The authors describe these as preliminary findings and call for larger trials.
- Participants
- 25
- Who or what was studied
- Head and neck cancer survivors with chronic lymphedema who had completed complete decongestive therapy
- Limits stated in the abstract
- The abstract describes a pilot study with a small sample (12 active, 13 control) and states that larger randomized trials are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Randomized controlled trial, Control group, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.